Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Free Report) is anticipated to issue its Q1 2025 quarterly earnings data before the market opens on Thursday, May 15th. Analysts expect Brainstorm Cell Therapeutics to post earnings of ($0.38) per share for the quarter.
Brainstorm Cell Therapeutics Price Performance
Shares of Brainstorm Cell Therapeutics stock opened at $1.21 on Wednesday. The firm has a fifty day moving average price of $1.21 and a two-hundred day moving average price of $1.59. The company has a market cap of $7.89 million, a PE ratio of -0.25 and a beta of 0.35. Brainstorm Cell Therapeutics has a fifty-two week low of $0.72 and a fifty-two week high of $10.05.
Wall Street Analyst Weigh In
Separately, StockNews.com initiated coverage on Brainstorm Cell Therapeutics in a research note on Tuesday. They set a “hold” rating on the stock.
About Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.
Further Reading
- Five stocks we like better than Brainstorm Cell Therapeutics
- Growth Stocks: What They Are, What They Are Not
- NVIDIA Stock Surges on Bullish News: How High Could It Climb?
- How to Start Investing in Real Estate
- Why Boeing May Be Ready to Take Off After Latest Developments
- EV Stocks and How to Profit from Them
- eBay Nears Big Breakout: Time to Buy the Under-the-Radar Winner?
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
